ALSO NOTED: Aldagen raises venture funds; Thrombin submitted to FDA;and much more...

> Aldagen has raised $17.3 million its third round of venture financing. The round was co-led by Harbert Venture Partners and Intersouth Partners. Release

> ZymoGenetics has filed rhThrombin for FDA approval. The therapy controls bleeding during surgery. Report

> Wyeth Pharmaceuticals has gained priority review status for its NDA covering Torisel for advanced renal cell carcinoma. Report

> PDL Biopharma has ended a discovery pact with Orphan Therapeutics for a new therapy to treat the liver disease terlipressin. Report

> Illumina has struck a "multimillion-dollar" deal to sell 1,000 of its HumanHap550 BeadChips to GlaxoSmithKline. Report

> PsychoGenics has struck a drug discovery pact with Eli Lilly, agreeing to use its technology to evaluate drug targets for neuropsychiatric disorders identified by Lilly researchers. Release

> In an accelerated move up, Pfizer CEO Jeff Kindler has been named chairman of Pfizer. He replaces Hank McKinnell three months ahead of schedule. Report

> Lonza Group has licensed its antibody and protein expression programs to Roche in a non-exclusive pact. No financial details were released. Report

> Neurogen has sold $40 million of common stock to institutional investors. Report

> The FDA has approved a generic version of Merck's prostate therapy Proscar. Report

And Finally... Researchers have demonstrated that rats have visual dreams while they sleep. The research sheds light on what human dreams mean. Release

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.